Dynamic Management of Lung Cancer Care During Surging COVID-19

Wang, Annie; Chang, Stephanie H.; Kim, Eric J.; Bessich, Jamie L.; Sabari, Joshua K.; Cooper, Benjamin; Geraci, Travis C.; Cerfolio, Robert J.

doi:10.3389/fsurg.2021.663364

Cited by 9 publications

(10 citation statements)

References 37 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were also recommendations made to supportive care, for example for the widespread use of granulocyte colony stimulating factor injections to reduce the risk of hospitalization from febrile neutropenia [ 31 ]. Consequently, more stringent measures were taken to shelter this population from contracting the virus and many scheduled treatments (i.e., chemotherapy, radiotherapy, and surgery) during the beginning of the pandemic were postponed while adaptive approaches of delivering therapy were established [ 32 , 33 ]. Cancer services rapidly developed strategies to overcome this setback and continue cancer care while minimizing the risk of COVID-19 transmission.…”

Section: Impact Of the Management Of Patients With Cancermentioning

confidence: 99%

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Ali

Riches

2021

Cancers

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has caused considerable global disruption to clinical practice. This article will review the impact that the pandemic has had on oncology clinical trials. It will assess the effect of the COVID-19 situation on the initial presentation and investigation of patients with suspected cancer. It will also review the impact of the pandemic on the subsequent management of cancer patients, and how clinical trial approval, recruitment, and conduct were affected during the pandemic. An intriguing aspect of the pandemic is that clinical trials investigating treatments for COVID-19 and vaccinations against the causative virus, SARS-CoV-2, have been approved and conducted at an unprecedented speed. In light of this, this review will also discuss the potential that this enhanced regulatory environment could have on the running of oncology clinical trials in the future.

show abstract

Section: Impact Of the Management Of Patients With Cancermentioning

confidence: 99%

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Ali

Riches

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…There were also recommendations made to supportive care, for example for widespread use of granulocyte colony stimulating factor injections to reduce the risk of hospitalization from febrile neutropenia [27]. Consequently, more stringent measures were taken to shelter this population from contracting the virus and many scheduled treatments (i.e., chemotherapy, radiotherapy, and surgery) during the beginning of the pandemic were postponed whilst adaptive approaches of delivering therapy were established [28,29]. Cancer services rapidly developed strategies to overcome this setback and continue cancer care whilst minimizing the risk of COVID-19 transmission.…”

Section: Impact Of the Management Of Patients With Cancermentioning

confidence: 99%

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Ali¹,

Riches²

2021

Preprint

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has caused considerable global disruption to clinical practice. This article will review the impact that the pandemic has had on oncology clinical trials. It will assess the effect of the COVID-19 situation on the initial presentation and investigation of patients with suspected cancer. It will also discuss the impact of the pandemic on the subsequent management of cancer patients and how clinical trial approval, recruitment and conduct were affected during the pandemic. An intriguing aspect of the pandemic is that clinical trials investigating treatments for COVID-19 and vaccinations against the causative virus, SARS-CoV-2, have been approved and conducted at unprecedented speed. In light of this, this re-view will also discuss the potential that this enhanced regulatory environment could have on the running of oncology clinical trials in the future.

show abstract

“…Postoperatively, patients should be treated in negative-pressure isolation rooms. Furthermore, the number of visitors should be drastically reduced or visitors should be prohibited altogether for patients after surgical treatment during their hospital stay [ 14 , 25 , 30 , 59 , 61 , 62 ].…”

Section: Lung Cancer Surgery In the Covid-19 Eramentioning

confidence: 99%

“…Data has also shown that patients with underlying malignancies have higher mortality rates, which estimates ranging between 3.7 and 61.5% [ 12 , 13 ]. For lung cancer, previous studies have demonstrated that lung cancer patients have higher risks of contracting COVID-19 and are significantly more likely to develop severe (respiratory) symptoms, with an estimated mortality rate of 30–50% [ 14 , 15 , 16 , 17 ]. However, despite these increased risks, the provision of quality care for cancer patients remains vital [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Safety and Feasibility of Lung Cancer Surgery under the COVID-19 Circumstance

Berzenji

Vercauteren

Yogeswaran

et al. 2022

Cancers

View full text Add to dashboard Cite

The current coronavirus disease 2019 (COVID-19) pandemic has forced healthcare providers worldwide to adapt their practices. Our understanding of the effects of COVID-19 has increased exponentially since the beginning of the pandemic. Data from large-scale, international registries has provided more insight regarding risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and has allowed us to delineate specific subgroups of patients that have higher risks for severe complications. One particular subset of patients that have significantly higher risks of SARS-CoV-2 infection with higher morbidity and mortality rates are those that require surgical treatment for lung cancer. Earlier studies have shown that COVID-19 infections in patients that underwent lung cancer surgery is associated with higher rates of respiratory failure and mortality. However, deferral of cancer treatments is associated with increased mortality as well. This creates difficult situations in which healthcare providers are forced to weigh the benefits of surgical treatment against the possibility of SARS-CoV-2 infections. A number of oncological and surgical organizations have proposed treatment guidelines and recommendations for patients planned for lung cancer surgery. In this review, we summarize the latest data and recommendations for patients undergoing lung cancer surgery in the COVID-19 circumstance.

show abstract

Dynamic Management of Lung Cancer Care During Surging COVID-19

Cited by 9 publications

References 37 publications

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Safety and Feasibility of Lung Cancer Surgery under the COVID-19 Circumstance

Contact Info

Product

Resources

About